Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN) "TALISMAN"


Phase 2/3 Results N/A

Summary of Purpose

This is a double-blind parallel arm randomized trial aimed to assess efficacy and safety of intravenous Tenecteplase compared to intravenous Alteplase in eligible patients who present with symptoms of acute ischemic stroke within 3 to 4.5 hours from onset.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 22 September 2015.

1 Jan 2015 21 Jun 2014 1 Jun 2020 1 Jun 2020 1 Sep 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


Not available